An AI-designed AAV capsid engineered for skeletal muscle gene delivery has moved from option to full license, with Astellas Pharma (TSE: 4503) exercising its right under the companies' 2021 research collaboration to license the vector from Dyno Therapeutics. Astellas will pay Dyno a USD 15 million license fee and will assume full responsibility for preclinical, clinical, and commercialization activities. The capsid is the first muscle-targeted vector licensed from the collaboration and Dyno's second capsid license overall, following Roche's exercise of an option for a CNS-targeted capsid in January 2025.
The 2021 agreement, which established the option structure now being exercised, carried a USD 18 million upfront payment to Dyno at signing, with total potential value across all products exceeding USD 1.6 billion, or more than USD 235 million per product in milestones and royalties. Under the current exercise, Dyno is eligible to receive clinical development, regulatory, and commercial milestone payments, plus royalties on any resulting products; specific rates and trigger amounts were not disclosed.
Deal context
The licensed asset is a synthetic AAV capsid protein shell engineered using Dyno's machine learning platform, described by the company as trained on billions of in vivo sequence-function measurements. The capsid determines which tissues a gene therapy vector infects, how efficiently it transduces target cells, and how it interacts with the immune system — properties that wild-type AAV serotypes such as AAV9 and AAVrh74 address imperfectly for skeletal muscle applications. High doses required to achieve therapeutic delivery with natural serotypes have historically created safety concerns and manufacturing cost pressures in muscle gene therapy.
Dyno's platform, which the company calls CapsidMap, operates as a closed-loop design cycle: machine learning models propose candidate capsid sequences, large barcoded libraries are synthesized and tested in living animals, and sequencing data on all variants feeds back into the models. The company states that the skeletal muscle capsid licensed to Astellas demonstrates superior muscle targeting in nonhuman primates while retaining compatibility with existing AAV9-based manufacturing processes. The capsid is a preclinical-stage delivery vehicle; Astellas will select the therapeutic transgene and develop the full gene therapy product independently. No specific indication has been disclosed, and no clinical trial identifier is available at this stage.
The capsid's compatibility with established manufacturing infrastructure is relevant commercially. Novel capsids that require entirely new production systems add cost and timeline risk to gene therapy development — a factor that has complicated several programs using highly engineered vectors. Dyno's statement that the licensed capsid leverages existing AAV9-based processes, if confirmed through independent manufacturing validation, would reduce that barrier for Astellas.